The PTPN22 gain-of-function 1858T() genotypes correlate with low IL-2 expression in thymomas and predispose to myasthenia gravis

Genes and Immunity

Volumn 10, Issue 8, 2009, Pages 667-672

  Chuang, W Y ^a,b   Strobel P ^a,c   Belharazem, D ^c   Rieckmann, P ^d   Toyka, K V ^d   Nix, W ^e   Schalke, B ^f   Gold, R ^g   Kiefer, R ^h   Klinker, E ^d   Opitz, A ^d   Inoue, M ^a   Kuo, T T ^b   Muller Hermelink H K ^a   Marx, A ^a,c  

^a UNIVERSITY OF WÜRZBURG   (Germany)

^b CHANG GUNG UNIVERSITY COLLEGE OF MEDICINE   (Taiwan)

^c UNIVERSITY OF HEIDELBERG   (Germany)

^d UNIVERSITY OF WÜRZBURG   (Germany)

^e JOHANNES GUTENBERG UNIVERSITY   (Germany)

^f UNIVERSITY OF REGENSBURG   (Germany)

^g RUHR UNIVERSITY BOCHUM   (Germany)

^h Diakoniekrankenhaus ^*  (Germany)

Author keywords

CTLA 4; Myasthenia; Negative selection; PTPN22; Thymoma

Indexed keywords

CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; INTERLEUKIN 2; NON RECEPTOR PROTEIN TYROSINE PHOSPHATASE 22; T LYMPHOCYTE RECEPTOR; CYTOTOXIC T-LYMPHOCYTE ANTIGEN 4; LEUKOCYTE ANTIGEN; PTPN22 PROTEIN, HUMAN;

ADOLESCENT; ADULT; AGED; ARTICLE; CAUCASIAN; CHILD; CONTROLLED STUDY; FEMALE; GENE EXPRESSION; GENE FREQUENCY; GENETIC ASSOCIATION; GENETIC PREDISPOSITION; GENETIC VARIABILITY; GENOTYPE; GERMANY; HUMAN; MAJOR CLINICAL STUDY; MALE; MYASTHENIA GRAVIS; ONSET AGE; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; SINGLE NUCLEOTIDE POLYMORPHISM; THYMOMA; GENETICS; IMMUNOLOGY; MIDDLE AGED;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTIGENS, CD; EUROPEAN CONTINENTAL ANCESTRY GROUP; FEMALE; GENETIC PREDISPOSITION TO DISEASE; GENOTYPE; HUMANS; INTERLEUKIN-2; MALE; MIDDLE AGED; MYASTHENIA GRAVIS; POLYMORPHISM, SINGLE NUCLEOTIDE; PROTEIN TYROSINE PHOSPHATASE, NON-RECEPTOR TYPE 22; THYMOMA; THYMUS NEOPLASMS; YOUNG ADULT;

EID: 73849107060     PISSN: 14664879     EISSN: 14765470     Source Type: Journal    
DOI: 10.1038/gene.2009.64     Document Type: Article

References (28)

1. Marx A, Müller-Hermelink HK, Ströbel P. The role of thymomas in the development of myasthenia gravis. Ann N Y Acad Sci 2003; 998: 223-236.
2. Willcox N, Schluep M, Ritter MA, Schuurman HJ, Newsom-Davis J, Christensson B. Myasthenic and non-myasthenic thymoma. An expansion of a minor cortical epithelial cell subset? Am J Pathol 1987; 127: 447-460.
3. Ströbel P, Murumägi A, Klein R, Luster M, Lahti M, Krohn K et al. Deficiency of the autoimmune regulator AIRE in thymomas is insufficient to elicit autoimmune polyendocrino-pathy syndrome type 1 (APS-1). J Pathol 2007; 211: 563-571.
4. high genotype is associated with myasthenia gravis in thymoma patients. Ann Neurol 2005; 58: 644-648.
5. Bottini N, Musumeci L, Alonso A, Rahmouni S, Nika K, Rostamkhani M et al. A functional variant of lymphoid tyrosine phosphatase is associated with type I diabetes. Nat Genet 2004; 36: 337-338.
6. Criswell LA, Pfeiffer KA, Lum RF, Gonzales B, Novitzke J, Kern M et al. Analysis of families in the multiple autoimmune disease genetics consortium (MADGC) collection: the PTPN22 620W allele associates with multiple autoimmune phenotypes. Am J Hum Genet 2005; 76: 561-571.
7. Smyth D, Cooper JD, Collins JE, Heward JM, Franklyn JA, Howson JM et al. Replication of an association between the lymphoid tyrosine phosphatase locus (LYP/PTPN22) with type 1 diabetes, and evidence for its role as a general autoimmunity locus. Diabetes 2004; 53: 3020-3023.
8. Ueda H, Howson JM, Esposito L, Heward J, Snook H, Chamberlain G et al. Association of the T-cell regulatory gene CTLA4 with susceptibility to autoimmune disease. Nature 2003; 423: 506-511. (Pubitemid 36648570)
9. Zheng W, She JX. Genetic association between a lymphoid tyrosine phosphatase (PTPN22) and type 1 diabetes. Diabetes 2005; 54: 906-908.
10. Kyogoku C, Langefeld CD, Ortmann WA, Lee A, Selby S, Carlton VE et al. Genetic association of the R620W polymorphism of protein tyrosine phosphatase PTPN22 with human SLE. Am J Hum Genet 2004; 75: 504-507.
11. Michou L, Lasbleiz S, Rat AC, Migliorini P, Balsa A, Westhovens R et al. Linkage proof for PTPN22, a rheumatoid arthritis susceptibility gene and a human autoimmunity gene. Proc Natl Acad Sci USA 2007; 104: 1649-1654.
12. Vandiedonck C, Capdevielle C, Giraud M, Krumeich S, Jais JP, Eymard B et al. Association of the PTPN22*R620W polymorphism with autoimmune myasthenia gravis. Ann Neurol 2006; 59: 404-407.
13. Lee YH, Rho YH, Choi SJ, Ji JD, Song GG, Nath SK et al. The PTPN22 C1858T functional polymorphism and autoimmune diseases-a meta-analysis. Rheumatology (Oxford) 2007; 46: 49-56.
14. Vang T, Congia M, Macis MD, Musumeci L, Orrú V, Zavattari P et al. Autoimmune-associated lymphoid tyrosine phosphatase is a gain-of-function variant. Nat Genet 2005; 37: 1317-1319.
15. Bassiri H, Carding SR. A requirement for IL-2/IL-2 receptor signaling in intrathymic negative selection. J Immunol 2001; 166: 5945-5954.
16. Lefvert AK, Zhao Y, Ramanujam R, Yu S, Pirskanen R, Hammarström L. PTPN22 R620W promotes production of anti-AChR autoantibodies and IL-2 in myasthenia gravis. J Neuroimmunol 2008; 197: 110-113.
17. Anjos S, Nguyen A, Ounissi-Benkalha H, Tessier MC, Polychronakos C. A common autoimmunity predisposing signal peptide variant of the cytotoxic T-lymphocyte antigen 4 results in inefficient glycosylation of the susceptibility allele. J Biol Chem 2002; 277: 46478-46486.
18. Kouki T, Sawai Y, Gardine CA, Fisfalen ME, Alegre ML, DeGroot LJ. CTLA-4 gene polymorphism at position 49 in exon 1 reduces the inhibitory function of CTLA-4 and contributes to the pathogenesis of Graves' disease. J Immunol 2000; 165: 6606-6611.
19. Ströbel P, Helmreich M, Menioudakis G, Lewin SR, Rüdiger T, Bauer A et al. Paraneoplastic myasthenia gravis correlates with generation of mature naive CD4(+) T cells in thymomas. Blood 2002; 100: 159-166.
20. Buckley C, Douek D, Newsom-Davis J, Vincent A, Willcox N. Mature, long-lived CD4+ and CD8+ T cells are generated by the thymoma in myasthenia gravis. Ann Neurol 2001; 50: 64-72.
21. Hoffacker V, Schultz A, Tiesinga JJ, Gold R, Schalke B, Nix W et al. Thymomas alter the T-cell subset composition in the blood: a potential mechanism for thymoma-associated autoimmune disease. Blood 2000; 96: 3872-3879.
22. Buhlmann JE, Elkin SK, Sharpe AH. A role for the B7-1/ B7-2:CD28/CTLA-4 pathway during negative selection. J Immunol 2003; 170: 5421-5428.
23. Kwon H, Jun HS, Khil LY, Yoon JW. Role of CTLA-4 in the activation of single-and double-positive thymocytes. J Immunol 2004; 173: 6645-6653.
24. Matthews RJ, Bowne DB, Flores E, Thomas ML. Characterization of hematopoietic intracellular protein tyrosine phosphatases: description of a phosphatase containing an SH2 domain and another enriched in proline-, glutamic acid-, serine-, and threonine-rich sequences. Mol Cell Biol 1992; 12: 2396-2405.
25. Cohen S, Dadi H, Shaoul E, Sharfe N, Roifman CM. Cloning and characterization of a lymphoid-specific, inducible human protein tyrosine phosphatase, Lyp. Blood 1999; 93: 2013-2024.
26. Wu J, Katrekar A, Honigberg LA, Smith AM, Conn MT, Tang J et al. Identification of substrates of human protein-tyrosine phosphatase PTPN22. J Biol Chem 2006; 281: 11002-11010.
27. Fend F, Kirchner T, Marx A, Müller-Hermelink HK. B-cells in thymic epithelial tumours. An immunohistochemical analysis of intra-and extraepithelial B-cells. Virchows Arch B Cell Pathol Incl Mol Pathol 1993; 63: 241-247.
28. Giraud M, Taubert R, Vandiedonck C, Ke X, Lévi-Strauss M, Pagani F et al. An IRF8-binding promoter variant and AIRE control CHRNA1 promiscuous expression in thymus. Nature 2007; 448: 934-937.